Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

All-Trans-Retinoic Acid, Atezolizumab, and Bevacizumab for the Treatment of Patients with Refractory, Metastatic Colon Cancer

Trial Status: closed to accrual

This phase II trial tests how well all-trans-retinoic acid (ATRA), atezolizumab and bevacizumab work to treat patients with colon cancer that that has spread from where it first started (metastatic) and that has not responded to previous treatment (refractory). Tretinoin, also called all-trans retinoic acid, ATRA, retinoic acid, and vitamin A acid is in a class of medications called retinoids. It is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. Laboratory made form of tretinoin works by slowing or stopping the growth of cancer cells by causing immature blood cells to develop into normal blood cells. A monoclonal antibody, such as atezolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving ATRA, atezolizumab, and bevacizumab may work better to treat patients with refractory, metastatic colon cancer.